Risk prediction for clonal cytopenia: multicenter real-world evidence
Key Points
A 3-parameter CCRS model was devised specifically for patients diagnosed with clonal cytopenia.
Key Points
A 3-parameter CCRS model was devised specifically for patients diagnosed with clonal cytopenia.
Abstract
Key Points
This study illustrates the survival benefits of abatacept combined with CNI/MTX in patients with hematologic malignancies undergoing HCT.
The addition of abatacept may provide an approach for alternative donor pool expansion when HLA-identical sibling donors are unavailable.
Abstract